The FDA recently approved a new drug called lorcaserin (brand name Belviq) for the treatment of obesity. Lorcaserin causes an average of 13 lbs (5.8 kg) of weight loss over a year, compared to 5 lbs (2.2 kg) for placebo
(
1), which is less than the other recently approved drug Qsymia (formerly Qnexa; topiramate/phentermine).
Learning about obesity drugs is always a good opportunity to gain insight into the mechanisms that underlie the development and reversal of obesity. If you've been following this blog for a while, you already have a pretty good guess what organ this new drug acts on. Make your guess and read on!
Read more »
Terampuh.com
Published:
2012-08-04T20:13:00-07:00
Title:Lorcaserin: the Latest FDA-approved Obesity Drug
Rating:
5 On
1234 reviews